Literature DB >> 6284848

Granulocyte phagocytosis and killing virulent and avirulent serotypes of Streptococcus pneumoniae.

J H Braconier, H Odeberg.   

Abstract

Five commonly isolated Streptococcus pneumoniae serotypes (3, 6, 14, 19, and 23) and five rarely found serotypes (31, 35, 36, 42, and 43) were compared to elucidate whether increased resistance against granulocyte phagocytosis and killing could explain the restricted number of pneumococcal serotypes found in infections. There was a great variation in sensitivity among the serotypes to granulocyte killing. No consistent pattern was found when pathogenicity and resistance to granulocytes were compared. The results do not indicate that the increased tendency of pathogenic pneumococcal serotypes to cause infections is due to increased resistance to granulocytes. Monocyte killing of some pneumococal serotypes (6, 19, 23, 35, and 43) was also studied and found very similar to granulocyte killing. Defective granulocyte kiling of encapsulated pneumococci was due to impaired phagocytosis. Moreover, no correlation was found between the sensitivity of the serotypes to isolated intragranulocytic microbial systems (i.e., MPO, hydrogen peroxide, or CCP) and the sensitivity to killing by intact granulocytes or pathogenicity. The significance of both the classical and alternative complement pathways for pneumococcal opsonization was indicated by reduced, the residual phagocytosis in C2-deficient and MgEGTA-chelated serum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284848

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Anaerobic phagocytosis, killing, and degradation of Streptococcus pneumoniae by human peripheral blood leukocytes.

Authors:  M Thore; S Löfgren; A Tärnvik; T Monsen; E Selstam; L G Burman
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

3.  Interference of Staphylococcus aureus lipase with human granulocyte function.

Authors:  J Rollof; J H Braconier; C Söderström; P Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

4.  Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis.

Authors:  A Wellmer; J Gerber; J Ragheb; G Zysk; T Kunst; A Smirnov; W Brück; R Nau
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae.

Authors:  T Kelly; J P Dillard; J Yother
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

7.  Cross-reacting opsonic antibodies to clinically important pneumococcal serotypes after pneumococcal vaccination.

Authors:  J H Braconier; E B Myhre; H Odeberg
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

8.  Reduced opsonisation of protein A containing Staphylococcus aureus in sera with cryoglobulins from patients with active systemic lupus erythematosus.

Authors:  O Nived; C Linder; H Odeberg; B Svensson
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

9.  Characterisation of an oxidative response inhibitor produced by Streptococcus pneumoniae.

Authors:  F E Perry; C J Elson; T J Mitchell; P W Andrew; J R Catterall
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

10.  Granulocyte phagocytosis of Streptococcus pneumoniae in properdin-deficient serum.

Authors:  J H Braconier; H Odeberg; A G Sjöholm
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.